https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ANiacin%2F34%2Fen 2026-05-19T12:04:23Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Translations:Niacin/34/en&diff=117734&oldid=prev 2024-02-20T00:42:51Z

<p>Importing a new version from external source</p> <p><b>New page</b></p><div>===Mechanisms===<br /> Niacin reduces synthesis of low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), [[lipoprotein(a)]] and [[triglycerides]], and increases [[high-density lipoprotein]] cholesterol (HDL-C). The lipid-therapeutic effects of niacin are partly mediated through the activation of [[G protein-coupled receptor]]s, including [[hydroxycarboxylic acid receptor 2]] (HCA&lt;sub&gt;2&lt;/sub&gt;)and [[hydroxycarboxylic acid receptor 3]] (HCA&lt;sub&gt;3&lt;/sub&gt;), which are highly expressed in [[adipose tissue|body fat]]. HCA&lt;sub&gt;2&lt;/sub&gt; and HCA&lt;sub&gt;3&lt;/sub&gt; inhibit [[cyclic adenosine monophosphate]] (cAMP) production and thus suppress the release of free [[fatty acids]] (FFAs) from body fat, reducing their availability to the liver to synthesize the blood-circulating lipids in question. A decrease in free fatty acids also suppresses liver expression of [[apolipoprotein C3]] and [[PPARGC1B|PPARg coactivator-1b]], thus increasing VLDL-C turnover and reducing its production. Niacin also directly inhibits the action of [[diacylglycerol O-acyltransferase 2]] (DGAT2) a key enzyme for triglyceride synthesis.</div>

FuzzyBot